Spruce Biosciences (SPRB) Non-Current Debt (2019 - 2026)

Spruce Biosciences (SPRB) posted quarterly Non-Current Debt of $5.5 million for Q1 2026, up 4306.45% quarter-over-quarter from $124000.0 in Q4 2024.

Spruce Biosciences (SPRB) Non-Current Debt (2019 - 2026) Analysis & Trends

Spruce Biosciences (SPRB) has reported Non-Current Debt for 7 consecutive years, with $5.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $5.5 million; the TTM figure through Mar 2026 stood at $5.5 million (changed N/A YoY), while the FY2024 annual figure was $124000.0, down 92.78% from the prior year.
Non-Current Debt advanced to $5.5 million in Q1 2026 per SPRB's latest filing, from $124000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $5.5 million in Q1 2026 and bottomed at $124000.0 in Q4 2024.
Historically, Non-Current Debt has averaged $2.5 million across 4 years, with a median of $2.5 million in 2023.
Annual changes were most pronounced in 2022 — Non-Current Debt fell 7.39% — and 2024, when it plunged 92.78%.
Spruce Biosciences' Non-Current Debt stood at $3.3 million in 2022, then plunged by 47.86% to $1.7 million in 2023, then slumped by 92.78% to $124000.0 in 2024, then jumped by 4306.45% to $5.5 million in 2026.
Business Quant data shows SPRB's Non-Current Debt at $5.5 million in Q1 2026, $124000.0 in Q4 2024, and $524000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	8.96 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.97 Mn
10	Spruce Biosciences	127.07 Mn	127.07 Mn	-	4.59 Mn

Download Data